The European Union has approved a third biosimilar referencing Lucentis (ranibizumab), STADA Arzneimittel and Xbrane BioPharma’s Ximluci, for the treatment of retinal conditions.
The European Commission granted marketing authorization for Ximluci, the third ranibizumab biosimilar to be approved in the European Union. The product was developed through a partnership between STADA Arzneimittel and Xbrane Biopharma and is expected to launch in early 2023.
The biosimilar references Lucentis (ranibizumab) and was approved to treat neovascular age-related macular degeneration (wet AMD), diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to choroidal neovascularization in adults. According to STADA and Xbrane, wet AMD affects about 7 million people across Europe and an estimated 500,000 new patients receive the diagnosis each year.
STADA and Xbrane entered into a partnership in July 2018, under which the companies are “jointly responsible for development and for manufacturing” the products contained within the agreement. STADA holds the marketing authorization and commercialization rights for Ximluci in the European Union, United States, several countries in the Middle East and North Africa region, and certain Asia-Pacific markets.
“We are proud to have worked with STADA to take this molecule, developed under the Xlucane name, from cell-line development to approval and manufacturing via our patented expression system in Europe…. Clinicians can prescribe Ximluci with confidence of producing comparable clinical outcomes to the reference product, Lucentis, based on extensive comparative quality studies and clinical data,” commented Martin Åmark, CEO of Xbrane.
Ximluci is the fifth biosimilar developed by STADA’s Specialty Care portfolio to be approved in Europe, following the approvals of Hukyndra (adalimumab biosimilar), Oyavas (bevacizumab biosimilar), Silapo (epoetin zeta biosimilar), and Movymia (teriparatide biosimilar). The marketing authorization application for the company’s pegfilgrastim biosimilar (Cavoley) was withdrawn in February 2019 because STADA could not address concerns raised by the Committee of Medicinal Products for Human Use by a given date.
“Having already successfully launched 5 biosimilars… we are excited to take our rapidly expanding Specialty Care portfolio into an important and growing therapeutic category—ophthalmology. This product authorized through STADA’s strategic partnership with Xbrane will help to increase patient access to biological treatments and optimize use of health care resources,” said Peter Goldschmidt, CEO of STADA, in a statement.
Prior to the approval of Ximluci, Byooviz was approved in August 2021 and Ranivisio was approved in August 2022. Byooviz was also approved in the United States in September 2021 and in Canada in March 2022. In August 2022, the FDA approved Cimerli, the first interchangeable ranibizumab biosimilar. A large portion of the anti-vascular endothelial growth factor market, which accumulated about €4 billion in 2021 and has grown by 8% annually between 2019 and 2021, comprises sales for ranibizumab products and aflibercept products.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.